Trials / Completed
CompletedNCT04204603
A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of CKD-506 Administered to Adult Subjects With Moderate-to- Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-506 | Tablets for oral administration |
| DRUG | Placebo | Tablets for oral administration |
Timeline
- Start date
- 2018-11-30
- Primary completion
- 2019-09-30
- Completion
- 2019-10-29
- First posted
- 2019-12-19
- Last updated
- 2019-12-30
Locations
38 sites across 5 countries: Czechia, Georgia, Poland, Russia, Ukraine
Source: ClinicalTrials.gov record NCT04204603. Inclusion in this directory is not an endorsement.